Shots:SNAP Biosciences & Monarch Therapeutics have entered into a licensing agreement for Monarch’s small molecule adaptor tech to develop & commercialize SNAP's Snap-Car NK cell therapy platform in oncology Financial terms remain undisclosed but incl. an upfront licensing payment, future development milestones, with net sales-based royaltiesMonarch’s tech enables SNAP-CAR cells to be…
